Inactive Instrument

Immunomedics, Inc.

Equities

IMMU

US4529071080

Biotechnology & Medical Research

Immunomedics : to Mail Letter to Stockholders Highlighting Unprecedented Progress Toward Enhanced Value Creation

January 12, 2017 at 10:00 pm IST

An Advanced Antibody-Based Therapeutics Company

Immunomedics is committed to be a leading, innovative biopharmaceutical company, dedicated to improving patient's health and quality of life with novel antibody-based therapeutics for the treatment of cancer, autoimmune and other serious diseases. Our work is driven by scientific excellence and the highest standards, in a culture of integrity, pride and dedication. In doing so, we create value for our shareholders and a rewarding environment for our employees.

Immunomedics Inc. published this content on 12 January 2017 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 12 January 2017 16:30:05 UTC.

Original documenthttp://www.immunomedics.com/pdfs/news/2017/pr01122017.pdf

Public permalinkhttp://www.publicnow.com/view/E889C8F658009379CB291AD4243E3BFC0D309F23

Latest news about Immunomedics, Inc.

Everest Medicines Limited announced that it has received $280 million in funding from Immunomedics, Inc.	27/23/27	CI
Gilead Sciences : Raises Product Sales Guidance on Remdesivir Demand, Narrows Earnings Outlook for 2020	11/21/11	DJ
Gilead Sciences : to Pay $1.4 Billion for Hepatitis Drug Maker MYR GmbH of Germany	10/20/10	DJ
Gilead Sciences : Quarterly Revenue Rises on Remdesivir Sales -- Update	29/20/29	DJ
Gilead Sciences : Quarterly Revenue Rises on Remdesivir Sales	29/20/29	DJ
Immunomedics, Inc. Announces Board Changes	24/20/24	CI
Immunomedics, Inc.(NasdaqGM:IMMU) dropped from S&P Biotechnology Select Industry Index	23/20/23	CI
Immunomedics, Inc.(NasdaqGM:IMMU) dropped from S&P Global BMI Index	23/20/23	CI
Immunomedics, Inc.(NasdaqGM:IMMU) dropped from S&P TMI Index	23/20/23	CI
Immunomedics, Inc.(NasdaqGM:IMMU) dropped from Russell 1000 Index	23/20/23	CI
Immunomedics, Inc.(NasdaqGM:IMMU) dropped from Russell Midcap Index	23/20/23	CI
Immunomedics, Inc.(NasdaqGM:IMMU) dropped from Russell 1000 Growth Index	23/20/23	CI
Immunomedics, Inc.(NasdaqGM:IMMU) dropped from Russell Midcap Growth Index	23/20/23	CI
Immunomedics, Inc.(NasdaqGM:IMMU) dropped from Russell 3000 Growth Index	23/20/23	CI
Immunomedics, Inc.(NasdaqGM:IMMU) dropped from Russell Small Cap Completeness Index	23/20/23	CI
Immunomedics, Inc.(NasdaqGM:IMMU) dropped from Russell 2500 Growth Index	23/20/23	CI
Immunomedics, Inc.(NasdaqGM:IMMU) dropped from Russell 3000 Index	23/20/23	CI
Immunomedics, Inc.(NasdaqGM:IMMU) dropped from Russell Small Cap Comp Growth Index	23/20/23	CI
Immunomedics, Inc.(NasdaqGM:IMMU) dropped from Russell 2500 Index	23/20/23	CI
Immunomedics, Inc.(NasdaqGM:IMMU) dropped from Russell 2500 Growth-Dynamic Index	23/20/23	CI
Immunomedics, Inc.(NasdaqGM:IMMU) dropped from Russell Midcap Gro-Dynamic Index	23/20/23	CI
Immunomedics, Inc.(NasdaqGM:IMMU) dropped from Russell Midcap Dynamic Index	23/20/23	CI
Immunomedics, Inc.(NasdaqGM:IMMU) dropped from Russell 2500 Dynamic Index	23/20/23	CI
Immunomedics, Inc.(NasdaqGM:IMMU) dropped from Russell 1000 Growth-Dynamic Index	23/20/23	CI
Immunomedics, Inc.(NasdaqGM:IMMU) dropped from Russell 1000 Dynamic Index	23/20/23	CI

Chart Immunomedics, Inc.

Duration

Period

More charts

Company Profile

Immunomedics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing monoclonal antibody-based products for the targeted treatment of cancer. Its technologies allow it to create humanized antibodies that can be used either alone in unlabeled or naked form, or conjugated with radioactive isotopes, chemotherapeutics, cytokines or toxins. It has a pipeline of six clinical-stage product candidates. Its portfolio of investigational products includes antibody-drug conjugates (ADCs) that are designed to deliver a payload of a chemotherapeutic directly to the tumor, while the managing overall toxic effects that are found with conventional administration of these chemotherapy agents. Its ADCs are sacituzumab govitecan (IMMU-132) and labetuzumab govitecan (IMMU-130). The Company also has a range of other product candidates that target solid tumors and hematologic malignancies, as well as other diseases, in various-stages of clinical and pre-clinical development.

Sector

Biotechnology & Medical Research

More about the company

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
MODERNA, INC.	+22.15%	4.66TCr
LONZA GROUP AG	+45.38%	4.17TCr
IQVIA HOLDINGS INC.	-2.37%	4.12TCr
ALNYLAM PHARMACEUTICALS, INC.	+33.84%	3.24TCr
CELLTRION, INC.	-6.35%	2.81TCr
ICON PUBLIC LIMITED COMPANY	+20.42%	2.82TCr
UNITED THERAPEUTICS CORPORATION	+48.83%	1.45TCr
MEDPACE HOLDINGS, INC.	+45.00%	1.37TCr
BIO-TECHNE CORPORATION	+0.06%	1.22TCr

Other Biotechnology & Medical Research